Showing items 1 - 4 of 4

Challenges and progress in adverse event ascertainment and reporting in clinical trials

- Lassere, M. N. D., Johnson, Kent R., Woodworth, T. G., Furst, D. E., Fries, J. F., Kirwan, J. R., Tugwell, P. S., Day, R. O., Brooks, P. M.

Generic patient self-report and investigator report instruments of therapeutic safety and tolerability

- Lassere, M. N. D., Johnson, Kent R., Van Santen, S., Carlton, K., Rappo, J., Michael, R., Kirwan, J. R., Edmonds, J. P.

Minimal disease activity for rheumatoid arthritis: a preliminary definition

- Wells, G. A., Boers, M., Shea, B., Brooks, P. M., Simon, L. S., Strand, C. V., Aletaha, D., Anderson, J. J., Bombardier, C., Dougados, M., Emery, P., Felson, D. T., Fransen, J., Furst, D. E., Hazes, J. M. W., Johnson, Kent R., Kirwan, J. R., Landewe, R. B. M., Lassere, M. N. D., Michaud, K., Suarez-Almazor, M., Silman, A. J., Smolen, J. S., van der Heijde, Dmfm, van Riel, Plcm, Wolfe, F., Tugwell, P. S.

Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module update

- Lassere, M. N. D., Johnson, Kent R., Boers, M., Carlton, K., Day, R. O., de Wit, M., Edwards, I. R., Fries, J. F., Furst, D. E., Kirwan, J. R., Tugwell, P. S., Woodworth, T. G., Brooks, P. M.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit